146 related articles for article (PubMed ID: 35366926)
1. Safety of stereotactic body radiation therapy for localized prostate cancer without treatment planning MRI.
Amarell K; Jaysing A; Mendez C; Haas JA; Blacksburg SR; Katz AE; Sanchez A; Tong A; Carpenter T; Witten M; Collins SP; Lischalk JW
Radiat Oncol; 2022 Apr; 17(1):66. PubMed ID: 35366926
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU; Ma TM; Lamb JM; Casado M; Wilhalme H; Low DA; Sheng K; Sharma S; Nickols NG; Pham J; Yang Y; Gao Y; Neylon J; Basehart V; Cao M; Steinberg ML
JAMA Oncol; 2023 Mar; 9(3):365-373. PubMed ID: 36633877
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
4. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
7. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.
Boyer MJ; Papagikos MA; Kiteley R; Vujaskovic Z; Wu J; Lee WR
Radiat Oncol; 2017 Jan; 12(1):14. PubMed ID: 28086825
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer.
Potters L; Rana Z; Lee L; Cox BW
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):334-342. PubMed ID: 30721721
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.
Katz AJ; Santoro M; Diblasio F; Ashley R
Radiat Oncol; 2013 May; 8():118. PubMed ID: 23668632
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease.
Lischalk JW; Blacksburg S; Mendez C; Repka M; Sanchez A; Carpenter T; Witten M; Garbus JE; Evans A; Collins SP; Katz A; Haas J
Radiat Oncol; 2021 Jul; 16(1):126. PubMed ID: 34243797
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
[TBL] [Abstract][Full Text] [Related]
14. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
Dess RT; Jackson WC; Suy S; Soni PD; Lee JY; Abugharib AE; Zumsteg ZS; Feng FY; Hamstra DA; Collins SP; Spratt DE
Cancer; 2017 May; 123(9):1635-1642. PubMed ID: 28001303
[TBL] [Abstract][Full Text] [Related]
15. High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients.
D'Agostino G; Franzese C; De Rose F; Franceschini D; Comito T; Villa E; Alongi F; Liardo R; Tomatis S; Navarria P; Mancosu P; Reggiori G; Cozzi L; Scorsetti M
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e173-e178. PubMed ID: 27389021
[TBL] [Abstract][Full Text] [Related]
16. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
Gurka MK; Chen LN; Bhagat A; Moures R; Kim JS; Yung T; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2015 Feb; 10():44. PubMed ID: 25890265
[TBL] [Abstract][Full Text] [Related]
17. Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.
Ong WL; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Davidson M; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A
Radiother Oncol; 2023 Apr; 181():109503. PubMed ID: 36754232
[TBL] [Abstract][Full Text] [Related]
18. Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
Leeman JE; Shin KY; Chen YH; Mak RH; Nguyen PL; D'Amico AV; Martin NE
Cancer; 2023 Oct; 129(19):3044-3052. PubMed ID: 37485697
[TBL] [Abstract][Full Text] [Related]
19. Proctitis following stereotactic body radiation therapy for prostate cancer.
Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
[TBL] [Abstract][Full Text] [Related]
20. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer.
Bergamin S; Eade T; Kneebone A; Booth J; Hsiao E; Schembri GP; Szymura K; Le A; Kwong C; Brown C; Hunter J; Hruby G
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1172-1178. PubMed ID: 32659332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
